Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction protein alpha 9 (GJA9)
- Target
- GJA9
- Molecular classification
- Connexin family (Gap junction protein), Ion channel (forms channels for ions and small molecules), Structural protein (forms membrane-spanning complexes)
01
Overview
Gap junction protein alpha 9 (GJA9) is a putative member of the connexin family, which comprises the structural subunits of gap junction channels. Gap junction channels are intercellular conduits formed by the alignment of two hemichannels (connexons), each composed of six connexin proteins. These channels facilitate direct exchange of ions, metabolites, and signaling molecules up to ~1 kDa in mass between adjacent cells, supporting electrical and metabolic coupling, tissue homeostasis, and synchronization of cellular activity[1][2][4]. Although gap junctions and connexins are fundamental for physiological processes in the nervous system, heart, skin, and other tissues[3][4], GJA9 is not well-characterized as an independent gene or protein in humans and its function, if any distinct from other connexins (e.g., GJA10, Connexin-59), is poorly described in current authoritative sources[2][4]. Some aliases of GJA9 overlap with GJA10 and may be a result of misannotation or confusion in the literature.
- Other names
- Gap junction alpha-9 proteinGJA9GJA10Cx58Cx59Connexin-58Connexin-59Gap junction alpha-10 protein59kDagap junction protein, alpha 9, 59kDa
02
Mechanism of action
Null (no established mechanisms for drugs acting on GJA9)
03
Biological functions
Cell-cell communication (direct cytoplasmic exchange through gap junctions)Synchronization of electrical activity (especially in neuronal and cardiac tissues)Regulation of tissue homeostasisSignal propagationMetabolic cooperation between cells
04
Disease associations
Null (not established for GJA9 specifically)Connexins are broadly implicated in:Neurological disorders (such as hereditary neuropathies)Cardiac arrhythmiasHearing lossSkin diseases
05
Safety considerations
Null (no safety concerns documented for targeting GJA9; general concerns for connexin/channel modulation include arrhythmia and disrupted tissue homeostasis)
06
Interacting drugs
Null (no drugs known to directly target GJA9; some gap junction inhibitors exist for the connexin family but not specifically for GJA9)
07
Biomarkers
Null (no established biomarkers for GJA9; some general gap junction protein/connexin biomarkers used in research)
Beyond the preview
Go deeper on Gap junction protein alpha 9 (GJA9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gap junction protein alpha 9 (GJA9).